Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study

What Was Tested

This registered phase 4 trial tested Semaglutide.

Many patients scheduled for their first ablation are overweight or have obesity, which is one of the strongest predictors of AF recurrence.

It had two arms (groups): Randomized to Semaglutide (experimental) and Standard of care (active comparator).

Participants randomized to the standard-of-care arm receive routine clinical management for atrial fibrillation and weight-related comorbidities without GLP-1 receptor agonist therapy. Usual care may include lifestyle counselling, blood pressure and lipid management, treatment of dysglycaemia, and guideline-directed preparation for first-time catheter ablation. No trial-specific medicinal product is administered. Pa.

The registry classes the interventions as behavioral and drug.

More on the Plan

Excess adiposity and related cardiometabolic risk factors are strongly linked to atrial structural remodeling and higher rates of post-ablation arrhythmia recurrence.

This randomized, open-label study allocates participants 1:1 to semaglutide plus standard of care or standard of care alone for at least three months before undergoing their first AF ablation.

All participants receive routine clinical management and continuous rhythm monitoring using an implantable loop recorder for 12 months post-ablation, with blinded adjudication of rhythm outcomes.

The study integrates real-world clinical practice, using only routine clinical assessments, registry data, and ILR monitoring without introducing additional invasive procedures.

Who Took Part

200 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Provision of written informed consent prior to participation. Age ≥18 years. Scheduled for first-time catheter ablation for atrial fibrillation using a pulmonary vein isolation (PVI) technique. Body Mass Index (BMI) ≥30 kg/m² (obesity) OR. Known diabetes type 2.

The full record lists 18 inclusion and 15 exclusion criteria; among the exclusions: morbid obesity (bmi \>40 kg/m²); current use of glp-1 receptor agonist therapy or dual agonist therapy within 6 months before screening; current use of dpp-iv inhibitors.

How the Study Was Run

Design: randomized, parallel-group and single-blind.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Semaglutide group and the comparison group ran side by side rather than switching.

Only one side, usually the participants, was kept unaware of whether Semaglutide was given.

Those kept unaware of assignments: outcomes assessor.

It started in 2026-03-23 with completion listed for 2028-12-30.

It ran at 1 site in Sweden.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Arrhythmia-free survival at 12 months after catheter ablation, excluding the 3-month blanking period, with recurrence defined as any ILR-detected AF, atrial flutter, or atrial tachycardia ≥30 seconds (time frame: 12 months post-ablation).

It also tracked 19 secondary outcomes, for example Atrial fibrillation burden (%) measured by implantable loop recorder, Per protocol analysis of the primary outcome, Time to first arrhythmia recurrence after the blanking period, Number of repeat ablations required to achieve sinus rhythm, Freedom from symptomatic AF without redo ablation and Symptom burden using questionnaires at baseline, ablation, 12 months.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide in 200 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.